Bioregnum, Insiders, R&D

Genentech team does some cutting-edge work on a new class of antibiotics — here’s why that’s important

One of my many mantras about R&D is that Big Pharma largely bowed out of basic antibiotic research to focus on more profitable ventures — leaving the field mostly to smaller biotech players which have been fielding some of the new players with marginal commercial potential.

And now Genentech wants to spoil that meme.

A discovery team at Roche’s big biotech operation has been working on a new antibiotic for gram-negative bacteria. And now they have a preclinical candidate they say has real potential to go on to become the first breakthrough in that field in more than half a century.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 44,100+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->